NFE2L2 and glioblastoma: Temozolomide (TMZ)-resistant glioblastoma multiforme (GBM) cells exhibit mesenchymal and stemness traits and resist erastin-induced ferroptosis by activating the CYBB/NRF2/SOD2 pathway (86).